mouse inflammation cytokine antibody arrays  (R&D Systems)

Journal: Lupus

Article Title: Anti-IFNAR treatment does not reverse neuropsychiatric disease in MRL/ lpr lupus mice

doi: 10.1177/0961203319872265

Figure Lengend Snippet: RNA expression and serum cytokine levels. (a) Reverse transcription-polymerase chain reaction for selected ISGs was performed on RNA isolated from the spleen, cortex, and choroid plexus of Cohort 1B. A significant decrease was seen in IP10 levels in the spleen (left) and choroid plexus (right) (spleen: p = .023, choroid plexus: p = .0088) in the anti-IFNAR–treated mice (n = 7–9) when compared with the IgG control mice (n = 7–8). (b) A similar decrease was seen in IFIT1 levels in the brain cortex of anti-IFNAR vs IgG control antibody–treated mice (p = .012) (anti-IFNAR treated, n = 9; IgG isotype control, n = 7). Outliers for (a) and (b) were determined using GraphPad Prism 7 software and excluded. (c) Serum was pooled in each group (n = 9 per group) and tested using a protein array. Blots detecting CXCL5 and TNFRII, both known ISGs, are shown.

Article Snippet: 27 Mouse inflammation cytokine antibody array Terminal serum samples from Cohort 1B were separately pooled for each treatment group and analyzed using the RayBiotech Mouse Inflammation Ab array C1 (Peachtree Corners, GA) following the manufacturer’s instructions.

Techniques: RNA Expression, Reverse Transcription Polymerase Chain Reaction, Isolation, Software, Protein Array

Journal: Neurotherapeutics

Article Title: Early-Stage Treatment with Withaferin A Reduces Levels of Misfolded Superoxide Dismutase 1 and Extends Lifespan in a Mouse Model of Amyotrophic Lateral Sclerosis

doi: 10.1007/s13311-014-0311-0

Figure Lengend Snippet: Altered expression profiles of cytokines in spinal cord of superoxide dismutase 1 (SOD1) G93A mice after Withaferin A (WA) treatment. Expression analysis of cytokines as analyzed with cytokine array on protein levels revealed no significant difference between the treated and nontreated group: (A) monocyte chemotactic protein (MCP)-1 (WA: 0.1070 ± 0.005; vehicle: 0.1040 ± 0.004; n = ??; p =0.70); (B) interleukin (IL)-1β (WA: 0.0076 ± 0.0005; vehicle: 0.0080 ± 0.0000000009; n =3; p =0.45); (C) tumor necrosis factor (TNF)-α (WA: 0.005 ± 0.0005; vehicle: 0.006 ± 0.000000002; n =3; p =0.13). However, in the WA-treated group, there was a significant increase in (D) IL-10 (WA: 0.0089 ± 0.0000017; vehicle: 0.0056 ± 0.00029; n =3; p <0.01); (E) IL-4 (WA: 0.12 ± 0.01; vehicle: 0.1 ± 0.009; n =3; p =0.61); (F) IL-6 (WA: 0.006 ± 0.0008; vehicle: 0.002 ± 0.0002; n =3; p =0.04); (G) granulocyte colony stimulating factor (G-CSF) (WA: 0.04 ± 0.008; vehicle: 0.017 ± 0.003; n =3; p =0.11) ; (H) granulocyte macrophage (GM)-CSF (WA: 0.01 ± 0.0003; vehicle: 0.019 ± 0.00089; n =3; p =0.05); and (I) macrophage (M)-CSF (WA: 0.1700 ± 0.008481; vehicle: 0.1608 ± 0.005628; n =3; p =0.46). * p ≤0.05; ** p ≤ 0.01 by t test. IOD = ??

Article Snippet: The expression profile of inflammatory cytokines were performed with a mouse cytokine antibody array (Raybio Mouse Inflammation Antibody Array 1, Cat#AAM- INF-1; RayBiotech, Norcross, GA, USA) as previously described in detail [ ].

Techniques: Expressing